This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert R. Fenichel, PhD, MD; Raymond J. Lipicky, MD

Arch Intern Med. 1994;154(13):1429-1430.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THE COURSE of evaluation for approval, a single-component drug is occasionally found to be unambiguously less effective or more dangerous than others. Such a drug may, nevertheless, be a valuable addition to the armamentarium, but it will be approved only as a second-line therapy, to be used only after others have been found to be ineffective or contraindicated. For example, bepridil is approved for the treatment of chronic stable angina, but its associated adverse drug reactions (ADRs) are sufficiently more severe than those of other approved antianginal products that bepridil is not approved as first-line therapy.

Drugs like bepridil are unusual. Most single-component products are approved as first-line therapy. Betaxolol, bisoprolol, chlorthalidone, and hydrochlorothiazide are separately approved as first-line therapy for hypertension, so some physicians may find it unremarkable that fixed-dose combinations of betaxolol and chlorthalidone and of bisoprolol and hydrochlorothiazide are also approved as first-line therapy. In fact, . . . [Full Text PDF of this Article]

Author Affiliations
Division of Cardio-Renal Drug Products (HFD-110) Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane, Rockville, MD 20857

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?